Avanafil: The Second-Generation Treatment of Erectile Dysfunction

Authors:

^*Giovanni Corona,¹ Mario Maggi,² Emmanuele A. Jannini^2,3

1. Endocrinology Unit 1, Maggiore-Bellaria Hospital, Medical Department, Azienda-Usl Bologna, Bologna, Italy
2. Sexual Medicine and Andrology Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy
3. Endocrinology, Andrology, and Medical Sexology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
*Correspondence to [email protected]

Disclosure:

Giovanni Corona has received consultancy fees from Bayer, Besins, Otsuka, Eli Lilly, and Menarini. Emmanuele A. Jannini has received consultancies from Bayer, Bracco, Besins, GSK, Eli Lilly, Menarini, Pfizer, and Shionogi. Mario Maggi has received consultancy and speaker fees from Bayer, Eli Lilly, Menarini, Prostrakan, and Intercept.

Acknowledgements:

Medical writing assistance was provided by Dr Caroline Charles of Scilink Medical Writing, Biarritz, France.

Support:

The publication of this article was funded by The Menarini Group. The views and opinions expressed are those of the authors and not necessarily of The Menarini Group.

Received:

23.03.16

Accepted:

18.07.16

Citation:

EMJ. 2016;1[3]:61-69. DOI/10.33590/emj/10314434. https://doi.org/10.33590/emj/10314434.

Keywords:

Erectile dysfunction (ED), avanafil, phosphodiesterase (PDE)-5 inhibitors

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.